A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Plerixafor subcutaneous injection will be administered prior to apheresis.

Busulfan IV infusion will be administered as myeloablative conditioning therapy.

BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.